Results 101 to 110 of about 3,785 (146)

Valacyclovir versus valganciclovir for cytomegalovirus prophylaxis in kidney transplant recipients: a systematic review and comparative meta-analysis

Clinical Transplantation and Research
Background : Valganciclovir (ValG) is the most widely used drug for cytomegalovirus (CMV) prophylaxis in kidney transplant recipients (KTRs). However, it is associated with dose-limiting side effects and considerable costs.
Leonardo Januário Campos Cardoso, Kleuber Arias Meireles Martins, Paulo Vitor Marques, Ivan Petterson Santana Teixeira, Ester Magalhães, Juan Lima Minkauskas, Isabela Coutinho Faria, Filipe Melo Ribeiro   +7 more
doaj   +1 more source

Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review

Infection and Drug Resistance, 2019
Guy El Helou,1,2 Raymund R Razonable1,21Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA; 2William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USAAbstract ...
El Helou G, Razonable RR
doaj  

A Novel Case of CMV Resistance to Valganciclovir and Maribavir in a Renal Transplant Patient

Transplant International
Helen Pearce, Emma K Montgomery, Neil S. Sheerin, Helena Ellam   +3 more
semanticscholar   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Valganciclovir

Drugs, 2012
Monique P Curran, Stuart Noble, Noble Stuart   +2 more
exaly   +6 more sources

Valganciclovir

Drugs, 2001
Valganciclovir is a prodrug of ganciclovir which has been developed for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. Oral valganciclovir is rapidly absorbed and hydrolysed to ganciclovir. The oral bioavailability of ganciclovir after oral valganciclovir administration is high.
M, Curran, S, Noble
openaire   +3 more sources

Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction

Clinical Transplantation, 2023
Valganciclovir (VGC) is the gold‐standard for cytomegalovirus (CMV) prophylaxis (PPX) after solid organ transplant (SOT). Letermovir (LTV) was recently approved in high‐risk kidney transplant and has reduced myelosuppressive toxicity. Conversion from VGC
M. Jorgenson, J. Descourouez, Christopher M Saddler, Jeannina A Smith, Jon S. Odorico, John P. Rice, D. Mandelbrot   +6 more
semanticscholar   +1 more source

A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients

Journal of the American Society of Nephrology, 2023
Significance Statement Although cytomegalovirus (CMV) infection is an important factor in the pathogenesis of kidney allograft rejection, previous studies have not determined the optimal CMV prevention strategy to avoid indirect effects of the virus.
T. Reischig, T. Vlas, Martin Kacer, K. Pivovarcikova, D. Lysák, J. Němcová, Petr Drenko, Jana Machová, M. Bouda, M. Šedivcová, S. Kormunda   +10 more
semanticscholar   +1 more source

Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis

Pediatric Transplantation, 2023
Cytomegalovirus (CMV) is associated with morbidity and mortality in solid organ transplant recipients (SOTR). Valganciclovir (VGC) is extensively used for prophylaxis.
R. Liverman, A. Serluco, G. Nance, Roshan P. George, Dellys Soler Rodriguez, S. Deshpande, Chad Y. Mao, R. Garro, I. Yildirim   +8 more
semanticscholar   +1 more source

Body surface area compared to body weight dosing of valganciclovir is associated with increased toxicity in pediatric solid organ transplantation recipients.

American Journal of Transplantation, 2023
Optimal dosing of valganciclovir (VGCV) for cytomegalovirus (CMV) prevention in pediatric solid organ transplantation recipients (SOTR) is controversial.
Salih Demirhan, F. Muñoz, Kristen G Valencia-Deray, C. Bocchini, L. Danziger-Isakov, S. Blum, Tanvi S. Sharma, G. Sherman, J. Boguniewicz, S. Bacon, M. Ardura, Gabriela M. Maron, Jose A. Ferrolino, M. Foca, B. Herold   +14 more
semanticscholar   +1 more source

Trough ganciclovir concentration as predictor of leukopenia in lung transplant recipients receiving valganciclovir prophylaxis

Transplant Infectious Disease, 2023
Valganciclovir is the first‐line agent for Cytomegalovirus prophylaxis after lung transplantation. However, its use is associated with a relatively high risk of hematological toxicity.
Yoshiki Katada, S. Nakagawa, M. Nagao, Keisuke Umemura, K. Itohara, Asami Nishikawa, S. Hashi, Yurie Katsube, D. Hira, A. Ohsumi, D. Nakajima, H. Date, T. Terada   +12 more
semanticscholar   +1 more source